ESR2 and non-small cell lung carcinoma: In vivo studies reveal that estradiol elevated PD-L1 and promotes immune evasion in NSCLC by upregulating the ERβ/SIRT1 axis, leading to increased PD-L1 expression and increased growth and metastasis of NSCLC with administration of estradiol [160] (Table 3).